Vantage logo

Ascendis shoots higher on pivotal win 

Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.

Vantage logo

SITC 2018 – No honey for Nektar

The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.